bestatin (ubenimex)

Subscribe to Selected New Research on bestatin

224 relevant articles (33 outcomes, 51 trials/studies) found for this Bio-Agent

Description: RN given refers to ((L-Leu)-(S-(R*,S*)))-isomer; structure

Also Known As:

ubenimex; 3-amino-2-hydroxy-4-phenylbutyryl-L-leucine; bestatin, (D-Leu)-(R-(R*,R*))-isomer; bestatin, (D-Leu)-(R-(R*,S*))-isomer; bestatin, (D-Leu)-(S-(R*,S*))-isomer; bestatin, (L-Leu)-(R-(R*,R*))-isomer; bestatin, (L-Leu)-(R-(R*,S*))-isomer; bestatin, (L-Leu)-(S-(R*,R*))-isomer; bestatin, (L-Leu)-(S-(R*,S*))-isomer, hydrochloride; (3-amino-2-hydroxy-4-phenylbutanoyl)-L-leucine

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Amino Acids: 8535

Branched-Chain Amino Acids: 524

Leucine: 2249

bestatin: 224

Essential Amino Acids: 335

Leucine: 2249

bestatin: 224

Experts

1.	Abe, Fuminori: 2 articles (06/2003 - 12/2002)
2.	Kikkawa, Fumitaka: 1 article (01/2008)
3.	Shibata, Kiyosumi: 1 article (01/2008)
4.	Nawa, Akihiro: 1 article (01/2008)
5.	Terauchi, Mikio: 1 article (01/2008)
6.	Tsukamoto, Hirohisa: 1 article (01/2008)
7.	Kajiyama, Hiroaki: 1 article (01/2008)
8.	Qian, Xi-Jun: 1 article (07/2006)
9.	Lin, Mao-Fang: 1 article (07/2006)
10.	Ueda, Yasuji: 1 article (12/2004)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1990 - "Subgrouping of the patient material gave no evidence that the clinical efficacy of bestatin is related to sex, tumor category or malignancy grade." 07/01/1987 - "Values of T cell subsets in cancer patients recovered to the normal levels by Bestatin treatment" 07/01/1994 - "In the present study, the in vitro effects of ubenimex on the cytotoxic activity of peripheral blood lymphocytes (PBL) and spleen cells of cancer patients and the mechanism of killer cell activation were investigated" 01/01/1989 - "A trial on the possible prevention or retardation of human tumor appearance by application of bestatin after the age of 40 yr is indicated." 01/01/1989 - "Although several studies have demonstrated that bestatin has immunopotentiating effects in tumor-bearing subjects, the above results indicated that the mechanism of immunopotentiation by bestatin is not a direct stimulatory effect on B-cells." Order ALL the reference details at left...
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/1986 - "It is concluded that bestatin is useful for prolongation of survival of adult patients with ANLL, making for a longer remission duration especially in elderly patients and with few side effects." 01/01/1990 - "Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults." 11/01/1995 - "We encountered a 71-year-old female with acute myelogenous leukemia (AML, M1), who maintained a steady hematological state for 22 months under ubenimex monotherapy" 11/01/1995 - "Hematological stability under ubenimex monotherapy in a patient with acute myelogenous leukemia developing marrow karyotypic changes during the course]" 08/01/1993 - "Ubenimex in the treatment of acute nonlymphocytic leukemia in adults." Order ALL the reference details at left...
3.	Melanoma (Melanoma, Malignant) 01/01/1985 - "These findings suggest that Bestatin is a very useful agent for treating for stage Ib and II malignant melanomas." 04/01/2006 - "We investigated the effect of three bestatin derivatives on A375 human melanoma cells and in vitro" 12/08/2004 - "Oral administration of bestatin (100-200 mg/kg/day) was found to significantly inhibit the melanoma cell-induced angiogenesis in a mouse dorsal air sac assay" 06/01/1985 - "For this reason, the data from phase III studies of Bestatin, including previously reported findings on malignant melanoma, proved Bestatin to be useful in treating stage Ib and II malignant melanoma, but were only suggestive of its potential indication in the treatment of other malignant tumors of the skin" 04/01/2006 - "In our previous report, bestatin inhibited the tumor cell invasion and the angiogenesis induced by the inoculation of B16-BL6 melanoma cells into mice and capillary formation on human umbilical vein endothelial cells (HUVECs) in vitro" Order ALL the reference details at left...
4.	Carcinoma (Carcinomatosis) 04/16/2003 - "We conducted a prospective randomized, double-blind, placebo-controlled trial to determine whether postoperative adjuvant treatment with bestatin could prolong the survival of patients with completely resected stage I squamous-cell lung carcinoma" 04/16/2003 - "Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma." 01/01/1990 - "Autoradiographic study of tissue distribution of [3H]ubenimex in IMC carcinoma-bearing mice." 01/01/2007 - "CONCLUSION: The current data indicate the possible involvement of APN/CD13 in the development of OVCA, and suggest that clinical use of bestatin may contribute to better prognosis for ovarian carcinoma patients." 04/16/2003 - "CONCLUSIONS: Survival was statistically significantly better for patients with completely resected stage I squamous-cell lung carcinoma who were treated with bestatin as a postoperative adjuvant therapy than for those who received a placebo" Order ALL the reference details at left...
5.	Stomach Neoplasms (Stomach Cancer) 01/01/1985 - "Bestatin was slightly effective in improving the three-year survival rates of gastric cancer patients, but this was not significant" 01/01/1991 - "The efficacy of Bestatin as adjuvant immunochemotherapy in patients with resectable gastric cancer was investigated" 03/01/1990 - "The efficacy of Bestatin as adjuvant immunochemotherapy for patients with resectable gastric cancer was investigated" 01/01/1991 - "Prospective randomized controlled study on bestatin in resectable gastric cancer." 03/01/1990 - "Prospective randomized controlled study on bestatin in resectable gastric cancer--third report." Order ALL the reference details at left...

Related Drugs and Biologics

1.	bestatin (ubenimex)
2.	Bleomycin (Blenoxane)
3.	Protease Inhibitors (Protease Inhibitor)
4.	Picibanil
5.	actinonin
6.	Prostaglandin D2
7.	Levamisole (Decaris)
8.	Immunologic Factors (Immunomodulators)
9.	Hormones
10.	PS-K (PSK)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Immunotherapy
3.	Blood Transfusion (Blood Transfusions)
4.	Aftercare (After-Treatment)
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18530 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>